BRPI0816406A2 - uso de urato oxidase para o tratamento ou a profilaxia de distúrbios ou sequelas indiretas do coração ocasionadas por eventos isquêmicos ou de reperfusão. - Google Patents

uso de urato oxidase para o tratamento ou a profilaxia de distúrbios ou sequelas indiretas do coração ocasionadas por eventos isquêmicos ou de reperfusão.

Info

Publication number
BRPI0816406A2
BRPI0816406A2 BRPI0816406A BRPI0816406A BRPI0816406A2 BR PI0816406 A2 BRPI0816406 A2 BR PI0816406A2 BR PI0816406 A BRPI0816406 A BR PI0816406A BR PI0816406 A BRPI0816406 A BR PI0816406A BR PI0816406 A2 BRPI0816406 A2 BR PI0816406A2
Authority
BR
Brazil
Prior art keywords
ischemic
prophylaxis
treatment
urate oxidase
heart disorders
Prior art date
Application number
BRPI0816406A
Other languages
English (en)
Portuguese (pt)
Inventor
Schaefer Matthias
Linz Wolfgang
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0816406A2 publication Critical patent/BRPI0816406A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
BRPI0816406A 2007-09-05 2008-08-20 uso de urato oxidase para o tratamento ou a profilaxia de distúrbios ou sequelas indiretas do coração ocasionadas por eventos isquêmicos ou de reperfusão. BRPI0816406A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291072 2007-09-05
PCT/EP2008/006858 WO2009030373A1 (en) 2007-09-05 2008-08-20 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events

Publications (1)

Publication Number Publication Date
BRPI0816406A2 true BRPI0816406A2 (pt) 2017-05-16

Family

ID=38713162

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816406A BRPI0816406A2 (pt) 2007-09-05 2008-08-20 uso de urato oxidase para o tratamento ou a profilaxia de distúrbios ou sequelas indiretas do coração ocasionadas por eventos isquêmicos ou de reperfusão.

Country Status (22)

Country Link
US (1) US20100266567A1 (cg-RX-API-DMAC7.html)
EP (1) EP2197550A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011509920A (cg-RX-API-DMAC7.html)
KR (1) KR20100053609A (cg-RX-API-DMAC7.html)
CN (1) CN101801460A (cg-RX-API-DMAC7.html)
AR (1) AR068360A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008295145B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816406A2 (cg-RX-API-DMAC7.html)
CA (1) CA2697929A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008002623A1 (cg-RX-API-DMAC7.html)
CO (1) CO6260090A2 (cg-RX-API-DMAC7.html)
IL (1) IL204259A (cg-RX-API-DMAC7.html)
MA (1) MA31624B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010001976A (cg-RX-API-DMAC7.html)
MY (1) MY183770A (cg-RX-API-DMAC7.html)
NZ (1) NZ583635A (cg-RX-API-DMAC7.html)
PA (1) PA8794801A1 (cg-RX-API-DMAC7.html)
PE (1) PE20090642A1 (cg-RX-API-DMAC7.html)
TW (1) TW200927929A (cg-RX-API-DMAC7.html)
UY (1) UY31320A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009030373A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201000774B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114972A (en) * 1990-07-30 1992-05-19 Tsuyoshi Ohnishi Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities
EP1317258B1 (en) * 2000-06-28 2009-02-11 Merck & Co., Inc. Use of allopurinol for the treatment of hypertension
AU2003275160A1 (en) * 2002-09-20 2004-04-08 Oregon Health And Science University Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries
CN102816241B (zh) * 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
WO2005099758A2 (en) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Injectable bioartificial tissue matrix
US20070197512A1 (en) * 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof

Also Published As

Publication number Publication date
RU2010112867A (ru) 2011-10-10
IL204259A (en) 2013-06-27
PE20090642A1 (es) 2009-06-18
MA31624B1 (fr) 2010-08-02
NZ583635A (en) 2011-06-30
CO6260090A2 (es) 2011-03-22
MX2010001976A (es) 2010-03-10
EP2197550A1 (en) 2010-06-23
TW200927929A (en) 2009-07-01
UY31320A1 (es) 2009-04-30
AU2008295145A1 (en) 2009-03-12
WO2009030373A1 (en) 2009-03-12
AU2008295145B2 (en) 2013-12-05
CN101801460A (zh) 2010-08-11
MY183770A (en) 2021-03-12
JP2011509920A (ja) 2011-03-31
US20100266567A1 (en) 2010-10-21
CL2008002623A1 (es) 2009-01-16
KR20100053609A (ko) 2010-05-20
PA8794801A1 (es) 2009-04-23
ZA201000774B (en) 2011-04-28
CA2697929A1 (en) 2009-03-12
AR068360A1 (es) 2009-11-11

Similar Documents

Publication Publication Date Title
NO2025029I1 (no) Entrectinib or isomers, tautomers, or pharmaceutically acceptable salts therof - forlenget
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
PL2504005T3 (pl) Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
CL2007003049A1 (es) Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
BRPI0912245A2 (pt) composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
NO20084526L (no) Tienpyrimidiner med MNKL/MNK2 inhiberende aktivitet for farmasøytiske sammensetninger
BRPI0817096A2 (pt) análogos de tiazolidinodiona para o tratamento de hipertensão
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
BRPI0918527A2 (pt) compostos para o tratamento de disturbios do cns
BR112012000254A2 (pt) análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas.
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0914802A2 (pt) Composto, pró-droga, medicamento, uso do composto ou uma pró-droga de mesmo.
DK2108260T3 (da) Sammensætning med biocid aktivitet til vandige præparater
BRPI1012128A2 (pt) composições contendo berberina ou seus análogos para tratamento de rosácea ou distúrbios de pele relacionados com face vermelha.
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
WO2010030598A3 (en) Pharmaceutical formulations comprising pemetrexed
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
BRPI1011768A2 (pt) agentes para o tratamento e/ou profilaxia de um distúrbio, e de uma doença, composição farmacêutica, kit, derivado de tiazol, composto, combinação, e, uso de um derivado de tiazol

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]